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Background: Glioblastoma (GBM) is the most common and lethal intracranial malignancy in adults, with dismal
prognosis despite multimodal therapies. Tectonic family member 1 (TCTN1) is a protein involved in a diverse range
of developmental processes, yet its functions in GBM remain unclear. This study aims to investigate expression
profile, prognostic value and effects of TCTN1 gene in GBM.
Methods: Protein levels of TCTN1 were assessed by immunohistochemical staining using a tissue microarray
constructed by a Chinese cohort of GBM patients (n = 110), and its mRNA expression was also detected in a subset
of this cohort. Kaplan-Meier analysis and Cox regression were performed to estimate the prognostic significance of
TCTN1. Similar analyses were also conducted in another two independent cohorts: The Cancer Genome Atlas
(TCGA) cohort (n = 528) and the Repository for Molecular Brain Neoplasia Data (REMBRANDT) cohort (n = 228). For
the TCGA cohort, the relationships between TCTN1 expression, clinical outcome, molecular subtypes and genetic
alterations were also analysed. Furthermore, proliferation of TCTN1 overexpressed or silenced GBM cells was
determined by CCK-8 assays.
Results: As discovered in three independent cohorts, both mRNA and protein levels of TCTN1 expression were
markedly elevated in human GBMs, and higher TCTN1 expression served as an independent prognostic factor
predicting poorer prognosis of GBM patients. Additionally, in the TCGA cohort, TCTN1 expression was dramatically
decreased in patients within the proneural subtype compared to other subtypes, and significantly influenced by the
status of several genetic aberrations such as CDKN2A/B deletion, EGFR amplification, PTEN deletion and TP53
mutation. The prognostic value of TCTN1 was more pronounced in proneural and mesenchymal subtypes, and was
also affected by several genetic alterations particularly PTEN deletion. Furthermore, overexpression of TCTN1
significantly promoted proliferation of GBM cells, while its depletion evidently hampered cell growth.
Conclusions: TCTN1 is elevated in human GBMs and predicts poor clinical outcome for GBM patients, which is
associated with molecular subtypes and genetic features of GBMs. Additionally, TCTN1 expression impacts GBM cell
proliferation. Our results suggest for the first time that TCTN1 may serve as a novel prognostic factor and a
potential therapeutic target for GBM.
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Accounting for 45% of all brain malignancies and 54% of
all human gliomas, glioblastoma (GBM) is the most
aggressive and lethal type of brain tumor [1,2]. Despite
multimodality therapies including maximal resection
and adjuvant chemotherapy and radiotherapy, the overall
outcome of patients with newly diagnosed GBM remains
dismal. According to the most recent report of The
Central Brain Tumor Registry of the United States
(CBTRUS), less than 5% of GBM patients survive five
years post diagnosis [1]. Clearly more effective therap-
ies are urgently needed and identification of valuable
prognostic biomarkers and potential molecular targets
is one key strategy to achieve this goal.
There are several different genetic alterations of import-
ant genes that may contribute to the pathogenesis of
GBM, and these aberrations may differ from patient to
patient. Therefore, treatment regimens for patients with
GBM may be more effective if they are tailored toward the
particular pathogenesis of patients’ neoplasm. In recent
years, substantial efforts have been made to explore
molecular profiles to better understand the pathogenesis
of GBM and biomarkers associated with patients’ survival.
There also have been several public resources that have
provided insight into the pathogenesis of GBM through
allowing researchers to correlate levels of gene expression
with clinical features, including The Cancer Genome Atlas
(TCGA) network [3] and Repository of Molecular Brain
Neoplasia Data (REMBRANDT) database [4]. Gene
expression studies of TCGA GBM tissues have identified
several distinct GBM molecular subtypes, namely classical,
mesenchymal, proneural and neural [5]. Thus, uncovering
new prognostic factors and molecular targets altered in
GBM, and revealing the association of their expression
profile with genetic alterations and molecular subtypes of
GBM, may provide opportunities to improve the clinical
outcome of GBM patients.
Tectonic family member 1 (TCTN1), was first identified
in 2006 as a potential regulator of the Hedgehog pathway
in patterning of the neural tube of mice, downstream of
smoothened and Rab23, and named tectonic after the
Greek word for builder due to its apparent involvement in
a diverse range of developmental processes [6]. In addition,
a recent study showed that TCTN1 was part of a
ciliopathy-associated protein complex and interacted with
several other proteins associated with ciliopathies [7]. Over
the past several years, the primary cilium was found to be a
complex signalling center where Hedgehog signalling was
regulated [8-10], and its disregulation was associated closely
to tumorigenesis [11-13]. Furthermore, Hedgehog pathway
was involved in the regulation of embryonic development,
cancer formation and maintenance, cancer stem cells
[14-16], and particularly development and progression of
human gliomas [17,18]. However, the function andprognostic value of TCTN1 in human glioma have never
been characterized.
In this study, we sought to investigate levels of TCTN1
expression in human GBMs using a tissue microarray
(TMA) of a Chinese GBM cohort and estimate its prog-
nostic value. We then validated the differential expression
and prognostic significance of TCTN1 in another two
independent datasets, namely the TCGA cohort and the
REMBRANDT cohort. For the TCGA cohort, we also
analysed the expression profile of TCTN1 according to
subtypes and genetic alterations of GBM. Finally, we
performed cell proliferation assays to explore the func-
tions of TCTN1 in GBM cells.
Methods
Patients and tissue samples
For the Chinese cohort of human glioblastoma (GBM)
patients in this study, 110 specimens were obtained at
the time of surgery at the Department of Neurosurgery in
Changzheng Hospital, Second Military Medical University
(SMMU), between January 2000 and December 2010.
Tissues of 16 normal brain samples were taken from
trauma outpatients. Clinicopathological information (age,
gender, clinical manifestations and extent of resection)
was obtained from medical records of the patients. Tumor
histology was confirmed independently by two neuropa-
thologists. Written informed consent was provided by all
participants. The study protocol and acquisition of tissue
specimens were approved by the Specialty Committee on
Ethics of Biomedical Research, SMMU, Shanghai, China.
Tissue microarray construction and
immunohistochemistry
Formalin-fixed, paraffin-embedded tissues were used to
construct an tissue microarray (TMA) as described previ-
ously [19,20] (Shanghai Biochip Company). Briefly, after
verification with hematoxylin and eosin (H&E) staining,
1.5 mm core punch sample was taken from each specimen
and cut as 4-μm-thick sections, which were then deparaf-
finized. Endogenous HRP activity was blocked with 3%
H2O2, and antigen retrieval was achieved by boiling in
sodium citrate buffer (pH 6.0). After blocking in 10% nor-
mal goat serum, immunostaining was performed using a
rabbit anti-TCTN1 antibody (ab105381; Abcam) at 1: 50
dilution. Finally, the visualization signal was developed
with 3,3’-diaminobenzidine (DAB), and the slides were
then counterstained in hematoxylin. As negative controls,
the sections were incubated with normal mouse serum
instead of the primary antibody. The scores of immuno-
histochemical staining were evaluated by two independent
pathologists in a blinded manner as described previously
[21-23]. Briefly, the expression of TCTN1 was scored by
estimating the proportion of tumor cells with positive
staining. High TCTN1 expression was defined as >10%
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proportion of < = 10% positive staining, as described in
previous studies [22,24-31].
RNA extraction, cDNA synthesis, and quantitative
real-time PCR
Fresh-frozen tissues from 8 human GBM patients and 8
normal brain samples were used for total RNA extrac-
tion using the Trizol reagent (Invitrogen) according to
the manufacturer’s instructions. Reverse transcription of
total RNA was conducted using ReverTra Ace qPCR RT
Master Mix (Toyobo), and quantitative real-time PCR
was performed using THUNDERBIRD SYBR qPCR Mix
(Toyobo) on ABI PRISM 7900HT instruments (Applied
Biosystems). The primers used for amplification of
TCTN1 were as follows: sense, 5’-CTGGATATTCC-
TACTGCTGCTAAAT-3’; antisense, 5’-CGAAGGAAA
TCTCAGAAACGA-3’. Glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) was used as the endogenous
control, using primers: sense, 5’-AGCCACATCGCT-
CAGACAC-3’; antisense, 5’-GCCCAATACGACCAAAT
CC-3’. The amplification was done in a total volume of
10 μl with the following conditions: an initial denatur-
ation step (95°C for 5 minutes), followed by 40 cycles of
denaturation (95°C for 15 seconds) and elongation (60°C
for 45 seconds), and a melting curve analysis of each
sample was used to check the specificity of amplification.
Each sample was assayed in triplicate, and the 2-ΔΔCt
method [32] was used to determine relative gene
expression.
In silico analyses of TCGA and REMBRANDT data
Another two independent datasets of GBMs, The Cancer
Genome Atlas (TCGA) [3] cohort (n = 528) and the Reposi-
tory of Molecular Brain Neoplasia Data (REMBRANDT)
[4] cohort (n = 228), were also included in the present
study. Expression data of TCTN1 and clinical information
of patients were obtained to validate the differential expres-
sion of TCTN1 and its prognostic value. For the TCGA
cohort, we also obtained common mutations, copy number
alterations and molecular subtypes data, which were avail-
able for part of the patients, to analyze the expression pro-
file of TCTN1 and its relationship with these items. In the
analysis of TCGA cohort, TCTN1 levels were dichotomized
to high and low at the median expression as previously
described [33-35]. For the REMBRANDT cohort, analyses
were performed on the website interface using the default
parameters [23,36].
Cell culture
U251 and U87 human GBM cell lines, and 293 T human
embryonic kidney cell line were purchased from Cell
Bank of Chinese Academy of Sciences (Shanghai, China),
and cultured in Dulbecco’s modified Eagle’s medium(DMEM; Life Technologies) supplemented with 10% fetal
bovine serum (FBS; Life Technologies) and penicillin/
streptomycin (100 units/ml and 100 μg/ml, respectively;
Life Technologies) and maintained at 37°C in an atmos-
phere of humidified air containing 5% CO2.
Gene overexpression and silencing
To overexpress TCTN1, coding sequence of TCTN1 gene
was cloned into a lentiviral vector pCDH-CMV-EF1-
copGFP (pCDH; System Biosciences) at the XhoI and EcoRI
restriction sites using primers: sense, 5’-CCGCTCGA-
GACTCCCTGGGAGATGAGGC-3’; antisense, 5’-GGAAT
TCTCAAACAAACGGGAAGAAGAAG-3’. To interfere
TCTN1 expression, the 21-nucleotide target sequence was
selected from the Public TRC Portal [37]: shTCTN1(clone
ID, TRCN0000297995), 5’-CTTCAGATTCGTTTCTGA-
GAT-3’. Sequence against LacZ gene served as a control
designated shControl: 5’-GGATCAGTCGCTGATTAAA-3’
[38]. Corresponding sense and antisense oligonucleotides
were synthesized, annealed and cloned into the HpaI - XhoI
sites of pLL3.7 lentiviral vector [39]. Lentiviral production
and transduction was conducted as previously described
[40]. Briefly, 293 T cells were co-transfected with the lenti-
viral expression vector pCDH-TCTN1 (pCDH empty
vector as a control) together with packaging plasmids pLP/
VSVG, pLP1 and pLP2 for overexpression, and with lenti-
viral vector pLL3.7-shTCTN1 (or shControl) and corre-
sponding packaging vectors psPAX2 and pMD2.G for gene
silencing, using Lipofectamine 2000 (Invitrogen) according
to the manufacturer’s instructions. The supernatants of
lentiviral particles were collected 48 hours post transfection
and filtered through 0.45-μm syringe filters (Millipore).
U251 and U87 cells were infected with the lentiviruses
carrying the expression vector or shRNA against TCTN1
along with corresponding controls.
Cell proliferation assay
Cell proliferation assay was performed as previously
described [41]. Briefly, different cell lines were seeded in 96-
well plates (1500–2000 cells/well) in six replicates. Cells were
allowed to grow for 4 days and cell proliferation analysis was
performed by Cell Counting Kit-8 (CCK-8; Dojindo Labora-
tories) assay at different time points according to the
manufacturer’s instructions. After an incubation of 2 hours
at 37°C, absorbance was measured at 450 nm using a
microplate reader iMark (Bio-Rad).
Western blot
Western blot was performed as previously described
[42]. Briefly, cells were lysed in the radioimmunopreci-
pitation assay (RIPA) buffer [50 mM Tris–HCl pH 8.0,
150 mM NaCl, 1% (v/v) NP-40, 0.5% (w/v) Sodium
deoxycholate, 0.1% (w/v) SDS] with protease inhibitors
cocktail (Sigma) added freshly. The lysates were
Table 1 Correlation between TCTN1 expression and







Male 74(67.3%) 20(27.0%) 54(73.0%)
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dene difluoride membranes (Millipore), which were
blocked in 5% milk for 1 hour and then probed with anti-
body against TCTN1(1:200; ab105381; Abcam), or actin
(1:4000; M20010; Abmart) as a loading control. Blots were
developed with Immobilon Western Chemiluminescent
HRP Substrate (Millipore) and visualized on G: Box Chemi
XR5 (Syngene).Female 36(32.7%) 13(36.1%) 23(63.9%)
Age (year) 0.211
≥53 52(47.3%) 19(36.5%) 33(63.5%)
<53 58(52.7%) 14(24.1%) 44(75.9%)
Tumor origin 0.670
Primary 95(86.4%) 28(29.5%) 67(70.5%)
Secondary 15(13.6%) 5(33.3%) 10(66.7%)
Seizure 0.349
No 96(87.3%) 27(28.1%) 69(71.9%)
Yes 14(12.7%) 6(42.9%) 8(57.1%)
IICP 0.836
No 59(53.6%) 17(28.8%) 42(71.2%)
Yes 51(46.4%) 16(31.4%) 35(68.6%)
Cystic degeneration 0.799
No 82(74.5%) 25(30.5%) 57(69.5%)
Yes 23(20.9%) 6(26.1%) 17(73.9%)
Necrosis 0.419
No 90(81.8%) 25(27.8%) 65(72.2%)
Yes 20(18.2%) 8(40.0%) 12(60.0%)
Edge 0.762Statistical analysis
Differences between two groups were analyzed by two-
tailed student’s t-test. The Fisher’s exact test (two-sided)
was conducted to analyze the correlation between TCTN1
expression and clinical characteristics. Pearson correlation
test was performed to analyze the correlation between
expression of TCTN1 and other genes. Overall survival
(OS) was defined as the elapsed time between diagnosis
and death or the last follow-up, and progression-free
survival (PFS) was defined as the time from diagnosis to
the date of tumor recurrence or further growth of residual
tumor or the date of death. Survival curves were plotted
by the Kaplan-Meier method and compared by the log-
rank test. To construct a model for the prediction of
survival, univariate and multivariate Cox proportional-
hazards regression analysis was performed, in which
clinical variables with log-rank P <0.05 in univariate
analysis were pooled into multivariate analysis. Values
presented are expressed as mean ± SD. SPSS (15.0)
software (SPSS Inc.) was used for all statistical analysis
and P <0.05 was considered statistically significant.Not clear 52(47.3%) 15(28.8%) 37(71.2%)
Clear 17(15.5%) 6(35.3%) 11(64.7%)
MTD (cm) 0.093
< 5 46(41.8%) 18(39.1%) 28(60.9%)
≥5 64(58.2%) 15(23.4%) 49(76.6%)
Resection 1.000
≥98% 84(76.4%) 25(29.8%) 59(70.2%)
< 98% 26(23.6%) 8(30.8%) 18(69.2%)
*P value was evaluated by Fisher's Exact Test (2-sided).
Abbreviations: IICP, increased intracranial pressure; MTD, mean tumor diameter.Results
GBM tissues exhibited increased protein and mRNA
expression of TCTN1 gene
In total, 110 cases of GBM patients were enrolled in the
Chinese GBM cohort. The median age at diagnosis was
53 years. Of the subjects, 74 (67.3%) were males. Details
of clinical characteristics were presented in Table 1. The
patients’ median overall survival (OS) was 12 months,
with 5 year survival rate of 4.3%. We assessed the
protein expression of TCTN1 in 110 GBMs and 16 nor-
mal brain tissues by immunohistochemistry assay using
a tissue microarray (TMA). We found that TCTN1 was
mainly expressed in nucleus (Figure 1A), and was sig-
nificantly increased in GBM tissues compared to nor-
mal controls (P =0.042, Additional file 1: Figure S1),
with no significant correlation with gender, age and
other clinicopathologic characteristics. We further
addressed whether TCTN1 gene was also up-regulated
at the transcriptional level. Total RNA was extracted
from a subset of 8 GBMs and 8 controls randomly
selected from this cohort and subjected to real-time
quantitative RT-PCR assay. The mRNA expression ofTCTN1 was considerably elevated in GBMs compared
to normal controls (Figure 1B, P =0.004).
TCTN1 served as an independent prognostic factor for
GBM patients
To investigate the correlation between TCTN1 expression
and clinical outcome, we first analysed the prognostic
significance of TCTN1 using Kaplan-Meier method. As
shown in Figure 1C and D, high TCTN1 expressers had
significantly shorter overall survival (OS) and progression-
free survival (PFS) than those with low TCTN1 expression
Figure 1 Expression and prognostic value of TCTN1 in a Chinese glioblastoma (GBM) cohort. (A) TCTN1 protein expression was analysed
by immunohistochemistry staining in human GBM specimens and normal brain samples, and representative images show high nuclear
expression of TCTN1 in GBMs. Magnification: ×50, left; ×200, right. Scale bars: 100 μm, left; 25 μm, right. (B) TCTN1 mRNA expression was analysed
by real time RT-PCR assay in human GBM samples, and GAPDH was used as an internal control. P value was determined by Student’s t test. (C-D)
Kaplan-Meier plots were estimated according to different TCTN1 immunoreactivity level for overall survival (C) and progression-free survival (D) of
GBM patients. P values were obtained from log-rank test, and hazard ratio (HR) and 95% confidence interval (CI) were calculated by univariate
Cox regression model.
Table 2 Multivariate Cox regression analysis of TCTN1
expression in GBM patients of 3 independent cohorts
Cohort Characteristics Multivariate cox regression
HR (95% CI) P
Chinese GBM (OS) TCTN1 (high vs. low) 1.69 (1.03-2.76) 0.037
Age (≥53 vs. <53) 1.54 (1.02-2.33) 0.038
(PFS) TCTN1 (high vs. low) 1.60 (1.01-2.52) 0.044
Age (≥53 vs. <53) 1.46 (0.98-2.18) 0.061
TCGA (OS) TCTN1 (high vs. low) 1.26 (1.03-1.54) 0.026
Age (≥60 vs. <60) 1.90 (1.55-2.33) <0.001
REMBRANDT (OS) TCTN1 (high vs. low) 1.58 (1.09-2.29) 0.017
Age (≥60 vs. <60) 2.23 (1.57-3.16) <0.001
Abbreviations: OS, overall survival; PFS, progression-free survival; CI, confidence
interval; HR, hazard ratio.
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pectively). Moreover, the subsequent univariate Cox
regression indicated that, besides TCTN1 expression
(HR =1.70, 95% CI =1.04-2.78, P = 0.033 for OS; HR =
1.63, 95% CI =1.03-2.56, P =0.036 for PFS), age at
diagnosis was also a significant prognostic factor. As
shown in Table 2, multivariate Cox regression revealed
that, after correction for patient age, elevated expres-
sion of TCTN1 protein was an independent risk
predictor of both OS (HR =1.69, 95% CI =1.03-2.76, P
=0.037) and PFS (HR =1.60, 95% CI =1.01-2.52, P
=0.044) for GBM patients in the Chinese cohort.
TCTN1 gene was overexpressed in GBMs and correlated
with several clinical features in the TCGA cohort
We next examined the expression profile and clinical
significance of TCTN1 in an independent cohort, i.e. the
TCGA cohort. Consequently, mRNA expression of TCTN1
was found to be increased in 98.86% (522/528) of the
GBMs compared to the normal brain controls (Figure 2A).
TCGA network described a robust gene expression-basedmolecular classification of GBM into 4 different subtypes,
namely classical, mesenchymal, neural, and proneural [5].
Thus, we further screened TCTN1 expression in different
molecular subtypes of GBMs and found that TCTN1
expression was dramatically decreased in proneural subtype
Figure 2 Expression of TCTN1 mRNA in GBM specimens of the TCGA cohort. (A) TCTN1 mRNA expression levels were detected in 528 clinical GBM
specimens and 10 cases of normal control tissue obtained by TCGA. The value represents log 2 of gene expression value of GBM to the average mRNA of
10 normal samples. The red samples (>0) indicate that the mRNA levels of these GBM tissues were higher than the average of normal brain tissues while
the green bars (<0) represent GBM sample with lower TCTN1 mRNA expression compared to normal tissues. (B-H) TCTN1 mRNA expression was
significantly different in subgroups of GBM according to subtypes and/or status of common mutations or copy number alterations (CNA) as indicated. “NC”,
no change; “Del”, deletion; “Amp”, amplification; “Wt”, wild-type; “Mut”, mutation. A single spot represents the TCTN1 expression value (log 2 scale) of an
individual patient, with a line in the middle representing the mean expression value. The difference in TCTN1 expression was determined by Student’s t-test.
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cantly elevated as compared to normal controls (P <0.0001;
Figure 2B).
In TCGA analysis of GBM, several genes were identi-
fied to be significantly mutated or have significant copy
number alterations (CNAs) [3,43]. To further explore
the expression profile of TCTN1 gene, we examined
associations between its expression and common genetic
alterations in GBM, including mutations in TP53, PTEN,
NF1, EGFR, RB1, PIK3R1, IDH1, PIK3CA, SPTA1,
ATRX, KEL, GABRA6, LZTR1, CTNND2, BRAF, amp-
lifications of EGFR, CDK4, PDGFRA, MDM2, MET,
MDM4, CDK6, MYCN, CCND2, PIK3CA, AKT3, and
deletions of CDKN2A, CDKN2B, PTEN, CDKN2C, RB1,
PARK2 and NF1. Consequently, we found that TCTN1
expression was significantly associated with mutations of
TP53, IDH1 and ATRX, amplifications of EGFR, PDGFRA
and MYCN, and deletions of CDKN2A, CDKN2B, PTEN
and PARK2 (Figure 2C-H, Additional file 1: Figure S2),
but not other aberrations.
Given that TCTN1 expression was also correlated with
transcriptional subtypes, we next addressed whether the
differential expression of TCTN1 according to abovemen-
tioned genetic alterations was dependent on specific
subtypes. As a result, CDKN2A or CDKN2B deleted cases
had significantly higher expression of TCTN1 in both
non-proneural (P <0.0001) and proneural (P =0.001) sub-
types compared with cases with no corresponding changes
(Figure 2C-D). Cases with TP53 mutation had lower levels
of TCTN1 expression than wild-type (P =0.004) in non-
proneural subtypes, while there was no significant dif-
ference in proneural subtype (Figure 2E). In contrast,
cases with amplification of EGFR or deletion of PTEN
or PARK2 had higher levels of TCTN1 expression than
cases with no corresponding changes only in proneural
subtype (P =0.045, 0.003, 0.014, respectively; Figure 2F-H).
However, the differential expression of TCTN1 according
to mutations of IDH1, ATRX or amplification of MYCN
and PDGFRA (Additional file 1: Figure S1A-D) lost any
statistical significance when we classified all cases into
non-proneural and proneural subgroups.
Given that previous studies linked TCTN1 to Hedge-
hog pathway in mouse embryonic development [6], we
investigated the associations between the expression
level of TCTN1 and common targets of Hedgehog
pathway, GLI1 and PTCH1, and found no significantly
correlation (Additional file 1: Figure S3).
TCTN1 was associated with prognosis of GBM patients in
the TCGA cohort
We further investigated the relationship between
TCTN1 expression and patients’ clinical outcome in the
TCGA cohort. We compared the survival of all GBM
patients with TCTN1 expression above or below themedian expression and found a statistically significant
disadvantage in overall survival for patients with higher
TCTN1 expression (Log-rank P =0.006; Cox regression
HR =1.32, 95% CI 1.08-1.61; Figure 3A). Multivariate
Cox regression further confirmed the prognostic value
of TCTN1 as an independent predictor (HR =1.60, 95%
CI =1.01-2.52, P =0.044; Table 2).
In addition, we also carried out survival analyses for
each molecular subtype and found that only the proneural
(Log-rank P =0.006; Cox regression HR =1.84, 95% CI
1.18-2.85) and mesenchymal (Log-rank P =0.037; Cox
regression HR =1.47, 95% CI 1.02-2.13) subtypes retained
statistical significance (Figure 3B-E).
Furthermore, we performed survival analysis stratified
by the genetic alteration status of abovementioned 10
genes with which TCTN1 expression was significantly
associated. As a consequence, TCTN1 expression was
associated with patients’ prognosis only in one specific
subgroup classified by the status of 7 genes (PTEN, EGFR,
PDGFRA, MYCN, PARK2, CDKN2A, CDKN2B; Figure 3F
and Additional file 1: Figure S4). A representative example
shown in Figure 3F indicated that prognostic significance
of TCTN1 was highly pronounced in individuals with
no PTEN change (Log-rank P <0.001; Cox regression
HR =2.84, 95% CI 1.58-5.14), but not significant in
PTEN deleted individuals. However, for the other 3
genes, namely TP53, IDH1 and ATRX, TCTN1 expres-
sion could not predict patients’ outcome in any sub-
group stratified by the genetic status of these genes.
The differential expression and prognostic value of TCTN1
was further validated in the REMBRANDT cohort
We further validated the differential expression and
prognostic significance of TCTN1 in GBMs of another
independent cohort, namely the REMBRANDT cohort.
Consistent with above mentioned TMA and TCGA
analysis, TCTN1 gene expression was remarkably in-
creased in GBMs (n = 228) than in normal controls
(n = 28; P <0.0001; Figure 4A). Moreover, high TCTN1
mRNA expression (n =132) could significantly predict
a worse overall survival for GBM patients in comparison
with low TCTN1 expression (n =49; Log-rank P =0.013;
HR =1.54, 95% CI 1.09-2.17; Figure 4B), which could also
serve as an independent prognostic factor in a multivariate
Cox regression model (HR =1.58, 95% CI =1.09-2.29,
P =0.017; Table 2).
Ectopic TCTN1 expression affected GBM cell proliferation
To explore the biological significance of TCTN1 in glioma,
we investigated whether it could affect cell proliferation.
TCTN1 was stably overexpressed or silenced in U251 and
U87 cells by lentiviruses infection, while the efficiency of
ectopic expression of TCTN1 was validated by real-time
PCR (Figure 5A) and western blot (Figure 5B) analysis. We
Figure 3 The prognostic value of TCTN1 in GBM specimens of the TCGA cohort. Kaplan-Meier plots were estimated according to different
TCTN1 gene expression for overall survival of all GBM patients (A) or the 4 different subtypes of GBM patients (B-E), or considering the copy
number alteration status of PTEN simultaneously (F). P values were obtained from log-rank test, while hazard ratio (HR) and 95% confidence
interval (CI) were determined by univariate Cox regression model.
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tion by CCK-8 assay within a 4-day period monitoring.
The results showed that in both U251 and U87 GBM cell
lines, upregulation of TCTN1 significantly promoted the
proliferation compared with the control groups, whereas
the blockade of endogenous TCTN1 expression markedly
inhibited cell growth in comparison with the controls
(Figure 5C).Figure 4 Expression and prognostic value of TCTN1 in GBMs of the R
in GBM samples in comparison to non-tumor controls. P value was calculat
different TCTN1 gene expression for overall survival of GBM patients. P valu
confidence interval (CI) were determined by univariate Cox regression modDiscussion
Glioblastoma (GBM) is the most malignant brain tumor
with dismal prognosis despite multimodal therapies, and
its pathogenesis is still far from elucidation. Molecular tar-
geted therapy represents promising avenue for the future
of effective treatment strategies for GBMs. Hence, more
valuable prognostic biomarkers and potential molecular
targets for gliomas are urgently needed to combat thisembrandt cohort. (A) TCTN1 gene has significantly higher expression
ed by Student’s t-test. (B) Kaplan-Meier curve was plotted according to
es were obtained from log-rank test, while hazard ratio (HR) and 95%
el.
Figure 5 Overexpression and knock-down of TCTN1 regulate GBM cell growth. (A) Overexpression and knock-down of TCTN1 gene in U251
and U87 human GBM cell lines were validated at mRNA level by real-time RT-PCR assays and GAPDH was used as an internal control. (B) Protein
level of TCTN1 was analysed by western blot assays and actin served as a loading control. (C) The cell growth curve of TCTN1 overexpression and
knockdown cells was assessed by CCK-8 assay. Each experiment was performed three times. Statistical analysis was performed using two tailed
Student’s t-test. *, P < 0.05.
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TCTN1 as a novel prognostic factor for GBM, which
was overexpressed in GBM tissues and could also
regulate the proliferation of GBM cells.
TCTN1 was a newly identified gene reported to be
involved in developmental processes, Hedgehog path-
way transduction and functions of primary cilium
[6,7]. Given that potent regulators of developmental
processes are frequently disrupted in tumorigenesis
[44], and the primary cilium and Hedgehog pathway
also play important roles in tumorigenesis [11,16], it is
to be expected that TCTN1 also contributes to tumor
development yet there have been no reports on it.
Hence, our study aimed to unveil the indispensable
role of TCTN1 in GBM progression. Our TMA
analysis and real-time PCR validation of a Chinese
GBM cohort revealed that TCTN1 was up-regulated inGBMs compared to normal controls, and high TCTN1
expression could predict shorter overall and progression-
free survival for GBM patients, as an independent prog-
nostic factor. Due to differences of genetic background
between populations [45], we further validated these find-
ings in another two independent international cohorts,
namely the TCGA cohort and the REMBRANDTcohort.
It was noteworthy that our immunohistochemical
staining experiments in GBM tissues found a nuclear
localisation of TCTN1, which was beyond our expect-
ation more or less, given the two important reports
that linked TCTN1 to Hedgehog pathway and primary
cilia by Dr. Jeremy F. Reiter’ group [6,7]. Actually, there
were several limitations of these studies. The former
revealed the involvement of Tctn1 (the mouse homolog
of human TCTN1) in Hedgehog signaling mediated
patterning of the neural tube of mice. Epistasis analyses
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transduction downstream of Ptch, Smo and Rab23. How-
ever, the findings were merely restricted in a mouse em-
bryonic development context and lacked direct evidences
using biochemical methods. The latter report found that
Tctn1 was essential for ciliogenesis in some embryonic tis-
sues such as the node and neural tube, and was required
to localize some proteins to the cilium in several other tis-
sues containing perineural and limb bud mesenchyme.
They further discovered Tctn1 as part of a transition zone
complex that controlled the organization of the transition
zone and ciliary membrane composition using some
mouse cell lines. However, the mechanisms underlying the
tissue specificity of Tctn1 complex function remain un-
clear and the findings were also context dependent. Thus,
whether TCTN1 regulate Hedgehog pathway still remains
unclear, particularly in the context of human cancer
biology.
Hedgehog signaling pathway was linked to tumorigenesis
in recent years. The most typical examples were basal cell
carcinoma (BCC) [46] and medulloblastoma (MB) [47], in
which mutations were identified in the regulatory compo-
nents of Hedgehog pathway. Although there were a few
reports regarding the regulation of Hedgehog signaling on
cancer stem cells in human gliomas [48,49], the role of
Hedgehog pathway in glioma remains in question.
To further investigate the relationship of TCTN1 and
Hedgehog pathway, we examined the transcriptional level
of GLI1, which is widely used to reflect Hedgehog pathway
activity [50], in TCGA database, and found it comparable
between GBMs and normal controls (data not shown). In
addition, we analyzed the relationship of TCTN1 and two
common target genes of Hedgehog pathway, GLI1 and
PTCH1, and found no significant correlation (Additional
file 1: Figure S3), indicating a rather weak link (if any)
between TCTN1 and Hedgehog pathway in GBMs.
The signal transduction of Hedgehog pathway was regu-
lated in the primary cilium, where TCTN1 was found to
be a component of a protein complex. In the mammalian
body, primary cilia were found on most epithelial and
stromal cells, and interestingly, transformed cells com-
monly lack cilia [51]. The role of primary cilia in cancer
progression were still controversial, maybe according to
the genetic background, as found in BCC [13] and MB
[12]. In addition, the prevalence and role of cilia on glioma
cells were poorly studied. It was reported that primary
cilia were deficient in several established GBM cell lines
compared to normal astrocytes [52]. Consistently, in
recently derived primary GBM cell lines and tumor biop-
sies, the majority of cells were unable to grow cilia [53].
Furthermore, it seems that the observed cilia of a small
portion of U251 GBM cells had no effect on cell prolifera-
tion, since depletion of Kif3a, a key component of cilio-
genesis, did not significantly affect cell growth [54].A remarkable feature of ciliogenesis is its cell cycle-
dependence [51,55-57]. In a system to study ciliary dynam-
ics in the hTERT-RPE1 cell lines, most of the cells were cili-
ated following serum starvation [56], which was widely
used to induce ciliogenesis in cultured cells [54,58,59].
However, it is a remarkable fact that ciliogenesis was
enhanced by serum starvation in neither established nor
recently derived primary GBM cell lines [52,53], although
that was the case in normal primary astrocytes [52].
Recently, it was reported that a cell-cycle-related kinase
(CCRK) may modulate ciliogenesis, and its regulation of
cell cycle was dependent on cilia in NIH3T3 cells [54]. In
addition, they found that depletion of CCRK could restore
cilia for a small fraction of U251 glioma cells, and inhibit
cell growth in part dependent on cilia. However, it is inter-
esting to note that depletion of CCRK did not block cells in
G0/G1 phase, suggesting other underlying mechanisms.
Our immunohistochemical staining experiments
showed primary expression of TCTN1 in cell nucleus
through a scan of more than one hundred GBM patients,
suggesting a weak link (if any) of TCTN1 and cilia in
human gliomas. Functions and molecular mechanisms of
TCTN1 in glioma warrant more investigations.
Characterized by dramatic molecular and histologic het-
erogeneity, GBM has recently been classified into distinct
subtypes with clinical relevance, opening the way for treat-
ments to be directed at subtype-specific mechanisms
[5,60]. In addition, for each molecular subtype, genetic
alterations in several key genes were significantly different.
The TCGA dataset offers an opportunity to investigate the
relationship between gene expression, molecular subtypes
and genetic alterations [61-64]. Therefore, we studied the
expression preference of TCTN1 in different subtypes and
its association with genetic aberrations in the TCGA
cohort. We found that TCTN1 was dramatically decreased
in the proneural subtype compared to other three
subtypes, which is in concordance with the previous find-
ing that the proneural subtype has a trend toward longer
survival compared with other subtypes [5]. For common
genetic alterations of GBM, TCTN1 was expressed in
correlation with 10 of them, i.e. mutations of TP53,
IDH1 and ATRX, amplifications of EGFR, PDGFRA
and MYCN, deletions of CDKN2A, CDKN2B, PTEN
and PARK2. Interestingly, for several of them (TP53
mutation, EGFR amplification, PTEN deletion and
PARK2 deletion), the association was restricted in non-
proneural or proneural subtype. For instance, within
non-proneural subgroups, the status of PTEN deletion
did not influence the levels of TCTN1 expression.
However, within the proneural subtype, patients with
no CNA of PTEN had dramatically lower TCTN1
expression compared to PTEN deleted patients. These
findings provided a clue for further research of the
regulation of TCTN1 expression in GBMs.
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expression and patients’ clinical outcome stratified by
different molecular subtypes and status of key genetic
alterations. As a consequence, when we looked at
TCTN1 impact on survival based on molecular sub-
type, only the proneural and mesenchymal subtype
retained significance. This analysis showed that the in-
fluence of TCTN1 expression on survival outcome
shows high subtype specificity with very strong effect
in the proneural and mesenchymal subtypes and
almost no effect in the other subtypes, thus the full
sample analysis effectively showed a dilution of the
effect in these two subtypes. In particular, patients
within the proneural subtype are expected to have a
slightly better prognosis compared to other subtypes
[5]. However, we noted that within the proneural
subgroup patients with high TCTN1 expression suffer
from especially poor prognosis than those with low
TCTN1 expression. Moreover, we also investigated
status of genetic alterations in TCGA dataset and
stratified the patients with GBM into two subgroups by
these molecular features. Our results showed that the
effect of TCTN1 expression on patients’ survival rely
on genetic background. It should be noted that,
TCTN1 could divide patients with no PTEN copy
number change into two subsets with totally distinct
outcome, although there was no difference for survival
of PTEN deleted patients with different TCTN1
expression, suggesting distinct effect of TCTN1 on
clinical outcome dependent on status of PTEN dele-
tion. Similar results could also be observed for other
several alterations, in detail, high expression of TCTN1
could predict poor prognosis for patients with no
EGFR change, no PDGFRA change, no MYCN change,
PARK2 deletion, CDKN2A deletion or CDKN2B dele-
tion. However, further perspective studies are still
warranted to unveil the underlying mechanisms.
Our analyses in these independent cohorts suggested
a key role of TCTN1 gene in tumorigenesis and pro-
gression of GBM, yet there has been no direct report
on its function in cancer biology. Thus we performed
in vitro experiments in two GBM cell lines through
enforced expression or depletion of TCTN1. Conse-
quently, we observed that TCTN1 overexpression evi-
dently promoted cell proliferation, whereas TCTN1
depletion dramatically hampered cell growth. These
results were consistent with the augmented expression
and prognostic value of TCTN1 in GBM clinical tis-
sues, suggesting that its survival detriment role may be
in part due to the ability of the TCTN1 protein to regu-
late proliferation of GBM cells. Functional study in cell
lines further highlighted potential therapeutic value of
TCTN1 in treatment of patients with GBM, albeit the
molecular mechanisms were still far from elucidation.Conclusions
In summary, TCTN1 was significantly elevated in hu-
man GBMs, and predicted poorer prognosis of GBM pa-
tients as a novel prognostic factor, which was found in a
TMA analysis of a Chinese cohort and confirmed in two
independent international cohorts. Furthermore, the ex-
pression profile and prognostic value of TNTN1 were
associated with different molecular subtype and genetic
alterations of GBM in analyses of the TCGA dataset.
Moreover, TCTN1 played an important role in prolifera-
tion of GBM cells, suggesting its potential application as
a therapeutic target for future GBM treatment.
Additional file
Additional file 1: Figure S1. TCTN1 protein expression was analysed by
immunohistochemistry staining and positive staining rate of TCTN1 in
normal brain samples and GBMs was indicated as a scatter plot. P value
was determined by Student’s t-test. Figure S2. TCTN1 mRNA expression
was significantly different in subgroups of GBMs in the TCGA cohort according
to status of IDH1 mutation (A), ATRX mutation (B), MYCN amplification (C) or
PDGFRA amplification (D) as indicated. A single spot represents the TCTN1
expression value (in log 2 scale) of an individual patient, with a line in the
middle representing the mean expression value. P values were determined by
Student’s t-test. Figure S3. Correlations between TCTN1 with GLI1(A) and
PTCH1(B) levels in TCGA cohort. Figure S4. Kaplan-Meier curves were plotted
according to different TCTN1 gene expression for overall survival of GBM
patients in the TCGA cohort stratified by the status of EGFR amplification
(A, B), PDGFRA amplification (C, D), MYCN amplification (E, F), PARK2 deletion
(G, H), CDKN2A deletion (I, J) and CDKN2B deletion (K, L) as indicated. P values
were obtained from log-rank test.
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